Patents Assigned to GUANGZHOU WELMAN NEW DRUG R&D CO., LTD.
-
Publication number: 20220305092Abstract: The use of lysozyme or combinations comprising the lysozyme in preparing a medicament for preventing or treating the novel coronavirus pneumonia COVID-19 and in preparing a food for assisting in preventing or treating the novel coronavirus pneumonia COVID-19 is disclosed. The lysozyme or the combination of the lysozyme, as provided by the present invention, can effectively inhibit cell damage caused by the novel coronavirus, inhibit the inflammatory factors expression induced by the novel coronavirus, ameliorate airway obstruction and decreased expiratory volume caused by lung lesions, and ameliorate intestinal barrier dysfunction. The lysozyme or the combination of the lysozyme has good effects on patients with high viral load, respiratory distress, impaired intestinal function, etc., and can reduce the novel coronavirus infection rate and the incidence rate of severe novel coronavirus pneumonia.Type: ApplicationFiled: May 9, 2020Publication date: September 29, 2022Applicants: GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD, GUANGZHOU XIN-CHUANGYI BIOPHARMACEUTICAL CO., LTD, GUANGZHOU WELMAN NEW DRUG R&D CO., LTD., XIANGBEI WELMAN PHARMACEUTICAL CO., LTD, NANJING KANGFUSHUN PHARMACEUTICAL CO., LTDInventors: Mingjie SUN, Tianyu SUN, Changqing LI
-
Publication number: 20220265785Abstract: Disclosed in the present invention is use of lysozyme in the preparation of a drug for preventing or treating a uric acid-related disease, a drug for reducing uric acid, and a drug for promoting uric acid excretion. Also disclosed in the present invention are a pharmaceutical composition for preventing or treating a uric acid-related disease, a pharmaceutical composition for reducing uric acid, and a pharmaceutical composition for promoting uric acid excretion, and a method for preventing or treating a uric acid-related disease, reducing uric acid and promoting uric acid excretion.Type: ApplicationFiled: July 17, 2020Publication date: August 25, 2022Applicants: GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD, GUANGZHOU XIN-CHUANGYI BIOPHARMACEUTICAL CO., LTD, GUANGZHOU WELMAN NEW DRUG R&D CO., LTD., XIANGBEI WELMAN PHARMACEUTICAL CO., LTD, NANJING KANGFUSHUN PHARMACEUTICAL CO., LTDInventors: Mingjie SUN, Tianyu SUN, Juanyan JIANG
-
Publication number: 20220257727Abstract: Disclosed are a pharmaceutical composition containing lysozyme and the use thereof in the preventing psoriasis, treating of psoriasis, and/or preventing of psoriasis recurrence. The pharmaceutical composition can significantly prolong the time before disease recurrence and significantly reduce the recurrence rate of diseases compared with the use of traditional oral drugs, immunosuppressive agents, biological agents, etc.Type: ApplicationFiled: May 29, 2020Publication date: August 18, 2022Applicants: GUANGZHOU CENTURY CLINICAL RESEARCH., LTD., GUANGZHOU XIN-CHUANGYI BIOPHARMACEUTICAL CO., LTD, GUANGZHOU WELMAN NEW DRUG R&D CO., LTD., XIANGBEI WELMAN PHARMACEUTICAL CO., LTD., NANJING KANGFUSHUN PHARMACEUTICAL CO., LTD.Inventors: Mingjie SUN, Tianyu SUN
-
Publication number: 20220193104Abstract: A compound for regulating body weight imbalance, a composition thereof and an application thereof. The inventor unexpectedly discovered that diosmin hydrogen sulfate derivatives have the effects of regulating body weight imbalance, and are expected to be developed as safe and effective weight imbalance regulators or used as synergists to improve the regulatory effects of existing weight imbalance regulators.Type: ApplicationFiled: April 24, 2020Publication date: June 23, 2022Applicants: GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD, GUANGZHOU XIN-CHUANGYI BIOPHARMACEUTICAL CO., LTD, XIANGBEI WELMAN PHARMACEUTICAL CO., LTD, GUANGZHOU WELMAN NEW DRUG R&D CO., LTD., NANJING KANGFUSHUN PHARMACEUTICAL CO., LTDInventors: Tianyu SUN, Mingjie SUN, Guixing DENG, Changqing LI
-
Patent number: 10668079Abstract: The present disclosure provides a composition consisting of ceftriaxone sodium and sulbactam sodium, a pharmaceutical formulation comprising the same and the application thereof. The composition is characterized by having an X-ray powder diffraction pattern with peaks at specific angles. The pharmaceutical formulation according to the present disclosure have better antibacterial activity and stability compared with known compositions, and are thus very suitable for the treatment of bacterial infections, especially for the treatment of refractory urogenital system infections caused by Neisseria gonorrhoeae which has drug-resistance to a variety of antibiotics (?-lactams, tetracyclines, macrolides, fluoroquinolones and aminoglycosides).Type: GrantFiled: November 2, 2016Date of Patent: June 2, 2020Assignees: XIANGBEI WELMAN PHARMACEUTICAL CO., LTD., GUANGZHOU WELMAN NEW DRUG R&D CO., LTD., NANJING KANGFUSHUN PHARMACEUTICAL CO., LTD.Inventor: Mingjie Sun
-
Publication number: 20190125755Abstract: The present invention provides a composition composed of ceftriaxone sodium and sulbactam sodium, a pharmaceutical composition comprising the same and the application thereof. The composition is characterized in that diffraction peaks at specific angles are included in the X-ray powder diffraction analysis spectrum. The pharmaceutical composition according to the present invention have better antibacterial activity and stability compared with known compositions, and are thus very suitable for the treatment of bacterial infections, especially for the treatment of refractory urogenital system infections caused by Neisseria gonorrhoeae which is drug-resistance to a variety of antibiotics (?-lactams, tetracyclines, macrolides, fluoroquinolones and aminoglycosides).Type: ApplicationFiled: November 2, 2016Publication date: May 2, 2019Applicants: XIANGBEI WELMAN PHARMACEUTICAL CO., LTD., GUANGZHOU WELMAN NEW DRUG R&D CO., LTD., NANJING KANGFUSHUN PHARMACEUTICAL CO., LTD.Inventor: Mingjie SUN
-
Publication number: 20110071225Abstract: A method for obtaining a sequoyitol-containing extract from a plant of genus Nephrolepis, comprising extracting with a solvent, recovering the solvent to give an extractum, subjecting the extractum to two-phase extraction and column chromatography, collecting the fractions containing sequoyitol, concentrating, filtration and drying. The main active ingredient of the extract obtained is sequoyitol, which can be used for treating diabetes and its complications.Type: ApplicationFiled: May 19, 2008Publication date: March 24, 2011Applicant: GUANGZHOU WELMAN NEW DRUG R&D CO., LTD.Inventors: Tianyu Sun, Yanli Wang, Yinyin Wang, You Lu, Ting Wang